Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025

Rhea-AI Summary

Reviva Pharmaceuticals (NASDAQ: RVPH) will present new data on the anti-inflammatory effects of brilaroxazine at Neuroscience 2025 in San Diego.

The late-breaker poster (Session A.10, LBP010) on Nov 15, 2025, 1:00–5:00 PM PT covers RECOVER Phase 3 double-blind results in acute schizophrenia and 12-month open-label extension data in clinically stable patients, focusing on BDNF and inflammatory cytokines. Abstracts and poster details are available on the Neuroscience 2025 website.

CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a late-breaker poster presentation at the 2025 Neuroscience meeting taking place November 15–19, 2025 in San Diego, CA.

Details for the poster presentation can be found below:

Title: Brilaroxazine treatment effects on BDNF and inflammatory cytokines in schizophrenia: RECOVER trial in acute and stable patients over 1 year
Session Name: A.10. Schizophrenia
Session Number: LBP010
Date and Time: Saturday, November 15, 2025, 1:00 – 5:00 PM PT

Abstracts and additional details can be found at the 2025 Neuroscience website.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

FAQ

What will Reviva (RVPH) present at Neuroscience 2025 on November 15, 2025?

A late-breaker poster on brilaroxazine effects on BDNF and inflammatory cytokines from RECOVER Phase 3 and 12-month open-label data.

When and where is Reviva's RVPH poster session at Neuroscience 2025?

Session A.10 (LBP010) on Saturday, November 15, 2025, between 1:00–5:00 PM PT in San Diego, CA.

Which trials are included in Reviva's RVPH poster on brilaroxazine?

Data come from the RECOVER Phase 3 double-blind trial in acute exacerbation of schizophrenia and a 12-month open-label extension in stable patients.

What biomarkers does Reviva report for brilaroxazine in the RVPH Neuroscience 2025 poster?

The poster focuses on treatment effects on BDNF and inflammatory cytokines.

Where can investors find the abstract and details for Reviva's RVPH Neuroscience 2025 poster?

Abstracts and poster details are available on the official Neuroscience 2025 website.